Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 29;18(6):652.
doi: 10.1186/s13054-014-0652-4.

Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model

Cheng-Ming Tsao  1   2 , Kai-Yi Li  3 , Shiu-Jen Chen  4   5 , Shuk-Man Ka  6 , Wen-Jinn Liaw  7   8   9 , Hsieh-Chou Huang  10   11 , Chin-Chen Wu  12   13
Affiliations

Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model

Cheng-Ming Tsao et al. Crit Care. .

Abstract

Introduction: The aim of this study was to investigate the effects of levosimendan on rodent septic shock induced by cecal ligation and puncture (CLP).

Methods: Three hours after peritonitis-induced sepsis, male Wistar rats were randomly assigned to receive an intravenous infusion of levosimendan (1.2 μg/kg/min for 10 min and then 0.3 μg/kg/min for 6 h) or an equivalent volume of saline and vehicle (5% dextrose) solution.

Results: The levosimendan-treated CLP animals had significantly higher arterial pressure and lower biochemical indices of liver and kidney dysfunction compared to the CLP animals (P < 0.05). Plasma interleukin-1β, nitric oxide and organ superoxide levels in the levosimendan-treated CLP group were less than those in CLP rats treated with vehicle (P < 0.05). In addition, the inducible nitric oxide synthase (iNOS) in lung and caspase-3 expressions in spleen were significantly lower in the levosimendan-treated CLP group (P < 0.05). The administration of CLP rats with levosimendan was associated with significantly higher survival (61.9% vs. 40% at 18 h after CLP, P < 0.05). At postmortem examination, the histological changes and neutrophil filtration index in liver and lung were significantly attenuated in the levosimendan-treated CLP group (vs. CLP group, P < 0.05).

Conclusions: In this clinically relevant model of septic shock induced by fecal peritonitis, the administration of levosimendan had beneficial effects on haemodynamic variables, liver and kidney dysfunction, and metabolic acidosis. (1) Lower levels of interleukin-1β, nitric oxide and superoxide, (2) attenuation of iNOS and caspase-3 expressions, and (3) decreases of neutrophil infiltration by levosimendan in peritonitis-induced sepsis animals suggest that anti-inflammation and anti-apoptosis effects of levosimendan contribute to prolonged survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progress of plasma (A) alanine aminotransferase (ALT), (B) aspartate aminotransferase (AST), (C) lactate dehydrogenase (LDH), (D) blood urea nitrogen (BUN), (E) creatinine, and (F) blood glucose during the experimental period. Depicted are the changes in plasma biochemical parameters in different groups of sham operation (SOP, n = 10), SOP plus levosimendan administration (SOP + LS, n = 6), cecal ligation and puncture (CLP, n = 10), CLP plus vehicle treatment (CLP + Veh, n = 6) and CLP plus levosimendan administration (CLP + LS, n = 12). Data are expressed as mean ± standard error of the mean. *P <0.05, all groups versus SOP. † P <0.05, CLP + LS versus CLP + Veh.
Figure 2
Figure 2
Progress of plasma (A) nitric oxide (NO) and (B) interleukin-1β (IL-1β) levels during the experimental period. Depicted are the changes of plasma NO and IL-1β levels in different groups of sham operation (SOP, n = 10), SOP plus Levosimendan administration (SOP + LS, n = 6), cecal ligation and puncture (CLP, n = 10), CLP plus vehicle treatment (CLP + Veh, n = 6) and CLP plus Levosimendan administration (CLP + LS, n = 12). Data are expressed as mean ± standard error of the mean. *P <0.05, all groups versus SOP; † P <0.05, CLP + LS versus CLP + Veh.
Figure 3
Figure 3
Superoxide levels of aorta, liver, spleen and pancreas at 18 h after surgery. Depicted are the changes in different groups of sham operation (SOP, n = 10), SOP plus Levosimendan administration (SOP + LS, n = 6), cecal ligation and puncture (CLP, n = 10), CLP plus vehicle treatment (CLP + Veh, n = 6) and CLP plus Levosimendan administration (CLP + LS, n = 12). Data are expressed as mean ± standard error of the mean. *P <0.05, all groups versus SOP, † P <0.05, CLP + LS versus CLP + Veh.
Figure 4
Figure 4
Expressions of (A) lung inducible nitric oxide (NO) synthase (iNOS) and (B) spleen-cleaved caspase 3. Depicted are the expressions of lung iNOS and spleen-cleaved caspase 3 at the end of the study in different groups of sham operation (SOP, n = 3), SOP plus Levosimendan administration (SOP + LS, n = 3), cecal ligation and puncture (CLP, n = 5), CLP plus vehicle treatment (CLP + Veh, n = 5) and CLP plus Levosimendan administration (CLP + LS, n = 5). Data are expressed as mean ± standard error of the mean. *P <0.05, all groups versus SOP, † P <0.05, CLP + LS versus CLP + Veh.
Figure 5
Figure 5
Histopathological studies of lung and liver. Light microscopy showed lung and liver sections of rats in groups of (A) sham operation, (B) cecal ligation and puncture (CLP), and (C) CLP plus Levosimendan administration. Sections were stained with haematoxylin and eosin. Arrows represent polymorphonuclear neutrophil infiltration in lung and liver. Each is shown at 400 × (original magnification).
Figure 6
Figure 6
Histopathological studies of spleen. Light microscopy showed spleen sections of rats in groups of (A) sham operation, (B) cecal ligation and puncture, and (C) CLP plus Levosimendan administration. Sections were stained with haematoxylin and eosin. Arrows represent apoptosis in the spleen. Each is shown at 400 × (original magnification).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.
    Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Crespo-Leiro MG, Delgado JF, Édes I, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Fruhwald S, Girardis M, Guarracino F, Harjola VP, Heringlake M, Herpain A, Heunks LM, Husebye T, Ivancan V, Karason K, Kaul S, Kivikko M, Kubica J, Masip J, Matskeplishvili S, Mebazaa A, Nieminen MS, Oliva F, Papp JG, Parissis J, Parkhomenko A, Põder P, Pölzl G, Reinecke A, Ricksten SE, Riha H, Rudiger A, Sarapohja T, Schwinger RH, Toller W, Tritapepe L, Tschöpe C, Wikström G, von Lewinski D, Vrtovec B, Pollesello P. Papp Z, et al. Card Fail Rev. 2020 Jul 8;6:e19. doi: 10.15420/cfr.2020.03. eCollection 2020 Mar. Card Fail Rev. 2020. PMID: 32714567 Free PMC article. Review.
  • [Heart in sepsis : Molecular mechanisms, diagnosis and therapy of septic cardiomyopathy].
    Martin L, Derwall M, Thiemermann C, Schürholz T. Martin L, et al. Anaesthesist. 2017 Jul;66(7):479-490. doi: 10.1007/s00101-017-0329-x. Anaesthesist. 2017. PMID: 28677016 Review. German.
  • Tissue heme oxygenase-1 exerts anti-inflammatory effects on LPS-induced pulmonary inflammation.
    Konrad FM, Knausberg U, Höne R, Ngamsri KC, Reutershan J. Konrad FM, et al. Mucosal Immunol. 2016 Jan;9(1):98-111. doi: 10.1038/mi.2015.39. Epub 2015 May 6. Mucosal Immunol. 2016. PMID: 25943274
  • Preclinical septic shock research: why we need an animal ICU.
    Guillon A, Preau S, Aboab J, Azabou E, Jung B, Silva S, Textoris J, Uhel F, Vodovar D, Zafrani L, de Prost N, Radermacher P; Translational Research Committee of the French Intensive Care Society (Société de Réanimation de Langue Française). Guillon A, et al. Ann Intensive Care. 2019 Jun 10;9(1):66. doi: 10.1186/s13613-019-0543-6. Ann Intensive Care. 2019. PMID: 31183570 Free PMC article. Review.
  • When sepsis affects the heart: A case report and literature review.
    Clemente G, Tuttolomondo A, Colomba D, Pecoraro R, Renda C, Della Corte V, Maida C, Simonetta I, Pinto A. Clemente G, et al. World J Clin Cases. 2015 Aug 16;3(8):743-50. doi: 10.12998/wjcc.v3.i8.743. World J Clin Cases. 2015. PMID: 26301236 Free PMC article.
See all "Cited by" articles

References

    1. Ani C, Farshidpanah S, Bellinghausen Stewart A, Nguyen HB: Variations in Organism-Specific Severe Sepsis Mortality in the United States: 1999-2008.Crit Care Med 2014, in press. - PubMed
    1. ProCESS Investigators. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F, Filbin MR, Shapiro NI, Angus DC. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683–1693. doi: 10.1056/NEJMoa1401602. - DOI - PMC - PubMed
    1. Zhou J, Qian C, Zhao M, Yu X, Kang Y, Ma X, Ai Y, Xu Y, Liu D, An Y, Wu D, Sun R, Li S, Hu Z, Cao X, Zhou F, Jiang L, Lin J, Mao E, Qin T, He Z, Zhou L, Du B, China Critical Care Clinical Trials Group (CCCCTG) Epidemiology and outcome of severe sepsis and septic shock in intensive care units in mainland china. PLoS One. 2014;9:e107181. doi: 10.1371/journal.pone.0107181. - DOI - PMC - PubMed
    1. Spronk PE, Zandstra DF, Ince C. Bench-to-bedside review: sepsis is a disease of the microcirculation. Crit Care. 2004;8:462–468. doi: 10.1186/cc2894. - DOI - PMC - PubMed
    1. Trzeciak S, Cinel I, Phillip Dellinger R, Shapiro NI, Arnold RC, Parrillo JE, Hollenberg SM, Microcirculatory Alterations in Resuscitation and Shock (MARS) Investigators Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med. 2008;15:399–413. doi: 10.1111/j.1553-2712.2008.00109.x. - DOI - PMC - PubMed

Publication types

MeSH terms